# Elion Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elion-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.eliontx.com
- Total disclosed funding: $25M
- Latest round: Series B (Jun 11, 2024)
- Investors on record: 3

## About

Founded in 2017 and based in New York, US, Elion Therapeutics, Inc., formerly Sfunga Therapeutics operates as a biotechnology company focused on the treatment of life-threatening invasive fungal infections. In June 2024, Elion Therapeutics, Inc. raised USD 81 million in series B funding co-led by investors AMR Action Fund and Deerfield Management, with participation from Illinois Ventures.

The firm’s product line includes F001, which is a polyene antifungal designed to reduce toxicity, particularly kidney impairment in patients. Moreover, the drug SF001 provides early antifungal therapy. The company develops therapies for combating invasive fungal infections developed from cancer treatment, organ transplants, or suffering from diseases like HIV/AIDS and severe COVID-19.

The company intends to use the June 2024 funding to support the development of its product.

## Funding rounds

- Series B, Jun 11, 2024, $25M — Illinois Ventures, Deerfield Management, AMR Action Fund

## Investors

- Illinois Ventures (https://capitalatlas.ai/funds/illinois-ventures) — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B
- AMR Action Fund (https://capitalatlas.ai/funds/amr-action-fund) — Series B